-
1
-
-
12244301581
-
In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: Determination of a pharmacokinetic/pharmacodynamic relationship
-
12538485 1:CAS:528:DC%2BD3sXnt1OrtA%3D%3D
-
Mendel DB, Laird AD, Xin X, Louie SG, Christensen JG, Li G, Schreck RE, Abrams TJ, Ngai TJ, Lee LB, Murray LJ, Carver J, Chan E, Moss KG, Haznedar JO, Sukbuntherng J, Blake RA, Sun L, Tang C, Miller T, Shirazian S, McMahon G, Cherrington JM (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327-337
-
(2003)
Clin Cancer Res
, vol.9
, pp. 327-337
-
-
Mendel, D.B.1
Laird, A.D.2
Xin, X.3
Louie, S.G.4
Christensen, J.G.5
Li, G.6
Schreck, R.E.7
Abrams, T.J.8
Ngai, T.J.9
Lee, L.B.10
Murray, L.J.11
Carver, J.12
Chan, E.13
Moss, K.G.14
Haznedar, J.O.15
Sukbuntherng, J.16
Blake, R.A.17
Sun, L.18
Tang, C.19
Miller, T.20
Shirazian, S.21
McMahon, G.22
Cherrington, J.M.23
more..
-
2
-
-
84860355062
-
Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma
-
22430274 1:CAS:528:DC%2BC38Xos1OgtLs%3D
-
Motzer RJ, Hutson TE, Olsen MR, Hudes GR, Burke JM, Edenfield WJ, Wilding G, Agarwal N, Thompson JA, Cella D, Bello A, Korytowsky B, Yuan J, Valota O, Martell B, Hariharan S, Figlin RA (2012) Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. J Clin Oncol 30:1371-1377
-
(2012)
J Clin Oncol
, vol.30
, pp. 1371-1377
-
-
Motzer, R.J.1
Hutson, T.E.2
Olsen, M.R.3
Hudes, G.R.4
Burke, J.M.5
Edenfield, W.J.6
Wilding, G.7
Agarwal, N.8
Thompson, J.A.9
Cella, D.10
Bello, A.11
Korytowsky, B.12
Yuan, J.13
Valota, O.14
Martell, B.15
Hariharan, S.16
Figlin, R.A.17
-
3
-
-
49249087039
-
Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma
-
18669461 1:CAS:528:DC%2BD1cXhtVGjs73L
-
Rini BI, Michaelson MD, Rosenberg JE, Bukowski RM, Sosman JA, Stadler WM, Hutson TE, Margolin K, Harmon CS, DePrimo SE, Kim ST, Chen I, George DJ (2008) Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma. J Clin Oncol 26:3743-3748
-
(2008)
J Clin Oncol
, vol.26
, pp. 3743-3748
-
-
Rini, B.I.1
Michaelson, M.D.2
Rosenberg, J.E.3
Bukowski, R.M.4
Sosman, J.A.5
Stadler, W.M.6
Hutson, T.E.7
Margolin, K.8
Harmon, C.S.9
Deprimo, S.E.10
Kim, S.T.11
Chen, I.12
George, D.J.13
-
4
-
-
84883440578
-
Circulating protein biomarkers of sunitinib (SU) and interferon-α (IFN-α) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC)
-
(abstr. 10525)
-
Harmon CS, Figlin RA, Hutson, TE, Michaelson MD, Negrier S, Kim ST, Huang X, Williams JA, Motzer RM (2011) Circulating protein biomarkers of sunitinib (SU) and interferon-α (IFN-α) efficacy in treatment (Tx)-naive patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 29(Suppl) (abstr. 10525)
-
(2011)
J Clin Oncol
, vol.29
-
-
Harmon, C.S.1
Figlin, R.A.2
Hutson3
Michaelson, M.D.4
Negrier, S.5
Kim, S.T.6
Huang, X.7
Williams, J.A.8
Motzer, R.M.9
-
5
-
-
84864333467
-
Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: A retrospective analysis of phase 2 and phase 3 trials
-
22759480 1:CAS:528:DC%2BC38XhtFajsLnF
-
Tran HT, Liu Y, Zurita AJ, Lin Y, Baker-Neblett KL, Martin AM, Figlin RA, Hutson TE, Sternberg CN, Amado RG, Pandite LN, Heymach JV (2012) Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials. Lancet Oncol 13:827-837
-
(2012)
Lancet Oncol
, vol.13
, pp. 827-837
-
-
Tran, H.T.1
Liu, Y.2
Zurita, A.J.3
Lin, Y.4
Baker-Neblett, K.L.5
Martin, A.M.6
Figlin, R.A.7
Hutson, T.E.8
Sternberg, C.N.9
Amado, R.G.10
Pandite, L.N.11
Heymach, J.V.12
-
6
-
-
84855173597
-
A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma
-
21464158 1:STN:280:DC%2BC38%2FptVagsQ%3D%3D 3276320
-
Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV (2012) A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23:46-52
-
(2012)
Ann Oncol
, vol.23
, pp. 46-52
-
-
Zurita, A.J.1
Jonasch, E.2
Wang, X.3
Khajavi, M.4
Yan, S.5
Du, D.Z.6
Xu, L.7
Herynk, M.H.8
McKee, K.S.9
Tran, H.T.10
Logothetis, C.J.11
Tannir, N.M.12
Heymach, J.V.13
-
7
-
-
84870661169
-
Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib vs sorafenib (AXIS trial)
-
(abstr. 7103)
-
Escudier B, Loomis AK, Kaprin A, Motzer R, Tomczak P, Tarazi J, Kim S, Gao F, Williams JA, Rini B (2011) Association of single nucleotide polymorphisms (SNPs) in VEGF pathway genes with progression-free survival (PFS) and blood pressure in metastatic renal cell carcinoma (mRCC) in the phase 3 trial of axitinib vs sorafenib (AXIS trial). In: European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical Oncology, Advocacy and Care. Eur J Cancer 47:S505 (abstr. 7103)
-
(2011)
European Multidisciplinary Cancer Congress on Integrating Basic and Translational Science, Surgery, Radiotherapy, Medical Oncology, Advocacy and Care. Eur J Cancer
, vol.47
, pp. S505
-
-
Escudier, B.1
Loomis, A.K.2
Kaprin, A.3
Motzer, R.4
Tomczak, P.5
Tarazi, J.6
Kim, S.7
Gao, F.8
Williams, J.A.9
Rini, B.10
-
8
-
-
53749093040
-
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
-
on behalf of ECOG 2100 Erratum in: J Clin Oncol (2009) 27:3070
-
Schneider BP, Wang M, Radovich M, Sledge GW, Badve S, Thor A, Flockhart DA, Hancock B, Davidson N, Gralow J, Dickler M, Perez EA, Cobleigh M, Shenkier T, Edgerton S, Miller KD, on behalf of ECOG 2100 (2008) Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J Clin Oncol 26:4672-4678. Erratum in: J Clin Oncol (2009) 27:3070
-
(2008)
J Clin Oncol
, vol.26
, pp. 4672-4678
-
-
Schneider, B.P.1
Wang, M.2
Radovich, M.3
Sledge, G.W.4
Badve, S.5
Thor, A.6
Flockhart, D.A.7
Hancock, B.8
Davidson, N.9
Gralow, J.10
Dickler, M.11
Perez, E.A.12
Cobleigh, M.13
Shenkier, T.14
Edgerton, S.15
Miller, K.D.16
-
9
-
-
79959316184
-
Pazopanib efficacy in renal cell carcinoma: Evidence for predictive genetic markers in angiogenesis-related and exposure-related genes
-
21576632 1:CAS:528:DC%2BC3MXpsVyqtrs%3D
-
Xu CF, Bing NX, Ball HA, Rajagopalan D, Sternberg CN, Hutson TE, de Souza P, Xue ZG, McCann L, King KS, Ragone LJ, Whittaker JC, Spraggs CF, Cardon LR, Mooser VE, Pandite LN (2011) Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes. J Clin Oncol 29:2557-2564
-
(2011)
J Clin Oncol
, vol.29
, pp. 2557-2564
-
-
Xu, C.F.1
Bing, N.X.2
Ball, H.A.3
Rajagopalan, D.4
Sternberg, C.N.5
Hutson, T.E.6
De Souza, P.7
Xue, Z.G.8
McCann, L.9
King, K.S.10
Ragone, L.J.11
Whittaker, J.C.12
Spraggs, C.F.13
Cardon, L.R.14
Mooser, V.E.15
Pandite, L.N.16
-
10
-
-
81255160848
-
Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal cell carcinoma treated with first-line sunitinib: A multicentre, observational, prospective study
-
22015057 1:CAS:528:DC%2BC3MXhsVSktrnK
-
Garcia-Donas J, Esteban E, Leandro-García LJ, Castellano DE, del Alba AG, Climent MA, Arranz JA, Gallardo E, Puente J, Bellmunt J, Mellado B, Martínez E, Moreno F, Font A, Robledo M, Rodríguez-Antona C (2011) Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study. Lancet Oncol 12:1143-1150
-
(2011)
Lancet Oncol
, vol.12
, pp. 1143-1150
-
-
Garcia-Donas, J.1
Esteban, E.2
Leandro-García, L.J.3
Castellano, D.E.4
Del Alba, A.G.5
Climent, M.A.6
Arranz, J.A.7
Gallardo, E.8
Puente, J.9
Bellmunt, J.10
Mellado, B.11
Martínez, E.12
Moreno, F.13
Font, A.14
Robledo, M.15
Rodríguez-Antona, C.16
-
11
-
-
84875511102
-
Predictive factors for response to treatment in patients with advanced renal cell carcinoma
-
22644070
-
Muriel López C, Esteban E, Astudillo A, Pardo P, Berros JP, Izquierdo M, Crespo G, Fonseca PJ, Sanmamed M, Martínez-Camblor P (2012) Predictive factors for response to treatment in patients with advanced renal cell carcinoma. Invest New Drugs 30:2443-2449
-
(2012)
Invest New Drugs
, vol.30
, pp. 2443-2449
-
-
Muriel López, C.1
Esteban, E.2
Astudillo, A.3
Pardo, P.4
Berros, J.P.5
Izquierdo, M.6
Crespo, G.7
Fonseca, P.J.8
Sanmamed, M.9
Martínez-Camblor, P.10
-
12
-
-
77957570088
-
Biomarkers predicting outcome in patients with advanced renal cell carcinoma: Results from sorafenib phase III treatment approaches in renal cancer global evaluation trial
-
20651059
-
Peña C, Lathia C, Shan M, Escudier B, Bukowski RM (2010) Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial. Clin Cancer Res 16:4853-4863
-
(2010)
Clin Cancer Res
, vol.16
, pp. 4853-4863
-
-
Peña, C.1
Lathia, C.2
Shan, M.3
Escudier, B.4
Bukowski, R.M.5
-
13
-
-
68549092780
-
Analysis of PTEN and HIF1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α
-
19526589 1:CAS:528:DC%2BD1MXhtVOnurnJ
-
Figlin RA, de Souza P, McDermott D, Dutcher JP, Berkenblit A, Thiele A, Krygowski M, Strahs A, Feingold J, Boni J, Hudes G (2009) Analysis of PTEN and HIF1a and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α. Cancer 115:3651-3660
-
(2009)
Cancer
, vol.115
, pp. 3651-3660
-
-
Figlin, R.A.1
De Souza, P.2
McDermott, D.3
Dutcher, J.P.4
Berkenblit, A.5
Thiele, A.6
Krygowski, M.7
Strahs, A.8
Feingold, J.9
Boni, J.10
Hudes, G.11
-
14
-
-
0036138580
-
Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma
-
11773181 1:CAS:528:DC%2BD38XnsFeqtg%3D%3D
-
Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M (2002) Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 20:289-296
-
(2002)
J Clin Oncol
, vol.20
, pp. 289-296
-
-
Motzer, R.J.1
Bacik, J.2
Murphy, B.A.3
Russo, P.4
Mazumdar, M.5
-
15
-
-
0034594628
-
New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
-
10655437 1:STN:280:DC%2BD3c7it1Gitg%3D%3D
-
Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
-
(2000)
J Natl Cancer Inst
, vol.92
, pp. 205-216
-
-
Therasse, P.1
Arbuck, S.G.2
Eisenhauer, E.A.3
Wanders, J.4
Kaplan, R.S.5
Rubinstein, L.6
Verweij, J.7
Van Glabbeke, M.8
Van Oosterom, A.T.9
Christian, M.C.10
Gwyther, S.G.11
-
16
-
-
78650149915
-
Aptamer-based multiplexed proteomic technology for biomarker discovery
-
21165148 1:CAS:528:DC%2BC3MXhtVSjtbY%3D 3000457
-
Gold L, Ayers D, Bertino J, Bock C, Bock A, Brody EN, Carter J, Dalby AB, Eaton BE, Fitzwater T, Flather D, Forbes A, Foreman T, Fowler C, Gawande B, Goss M, Gunn M, Gupta S, Halladay D, Heil J, Heilig J, Hicke B, Husar G, Janjic N, Jarvis T, Jennings S, Katilius E, Keeney TR, Kim N, Koch TH, Kraemer S, Kroiss L, Le N, Levine D, Lindsey W, Lollo B, Mayfield W, Mehan M, Mehler R, Nelson SK, Nelson M, Nieuwlandt D, Nikrad M, Ochsner U, Ostroff RM, Otis M, Parker T, Pietrasiewicz S, Resnicow DI, Rohloff J, Sanders G, Sattin S, Schneider D, Singer B, Stanton M, Sterkel A, Stewart A, Stratford S, Vaught JD, Vrkljan M, Walker JJ, Watrobka M, Waugh S, Weiss A, Wilcox SK, Wolfson A, Wolk SK, Zhang C, Zichi D (2010) Aptamer-based multiplexed proteomic technology for biomarker discovery. PLoS ONE 5:e15004
-
(2010)
PLoS ONE
, vol.5
, pp. 15004
-
-
Gold, L.1
Ayers, D.2
Bertino, J.3
Bock, C.4
Bock, A.5
Brody, E.N.6
Carter, J.7
Dalby, A.B.8
Eaton, B.E.9
Fitzwater, T.10
Flather, D.11
Forbes, A.12
Foreman, T.13
Fowler, C.14
Gawande, B.15
Goss, M.16
Gunn, M.17
Gupta, S.18
Halladay, D.19
Heil, J.20
Heilig, J.21
Hicke, B.22
Husar, G.23
Janjic, N.24
Jarvis, T.25
Jennings, S.26
Katilius, E.27
Keeney, T.R.28
Kim, N.29
Koch, T.H.30
Kraemer, S.31
Kroiss, L.32
Le, N.33
Levine, D.34
Lindsey, W.35
Lollo, B.36
Mayfield, W.37
Mehan, M.38
Mehler, R.39
Nelson, S.K.40
Nelson, M.41
Nieuwlandt, D.42
Nikrad, M.43
Ochsner, U.44
Ostroff, R.M.45
Otis, M.46
Parker, T.47
Pietrasiewicz, S.48
Resnicow, D.I.49
Rohloff, J.50
Sanders, G.51
Sattin, S.52
Schneider, D.53
Singer, B.54
Stanton, M.55
Sterkel, A.56
Stewart, A.57
Stratford, S.58
Vaught, J.D.59
Vrkljan, M.60
Walker, J.J.61
Watrobka, M.62
Waugh, S.63
Weiss, A.64
Wilcox, S.K.65
Wolfson, A.66
Wolk, S.K.67
Zhang, C.68
Zichi, D.69
more..
-
17
-
-
59749098453
-
'Fit-for-purpose' validation for SearchLight Multiplex ELISAs of angiogenesis for clinical trial use
-
19174166 1:CAS:528:DC%2BD1MXitVCnt7k%3D
-
Backen AC, Cummings J, Mitchell C, Jayson G, Ward TH, Dive C (2009) 'Fit-for-purpose' validation for SearchLight Multiplex ELISAs of angiogenesis for clinical trial use. J Immunol Methods 342:106-114
-
(2009)
J Immunol Methods
, vol.342
, pp. 106-114
-
-
Backen, A.C.1
Cummings, J.2
Mitchell, C.3
Jayson, G.4
Ward, T.H.5
Dive, C.6
-
18
-
-
40749139487
-
Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer
-
18172253 1:CAS:528:DC%2BD1cXoslOn
-
Kim JG, Chae YS, Sohn SK, Cho YY, Moon JH, Park JY, Jeon SW, Lee IT, Choi GS, Jun SH (2008) Vascular endothelial growth factor gene polymorphisms associated with prognosis for patients with colorectal cancer. Clin Cancer Res 14:62-66
-
(2008)
Clin Cancer Res
, vol.14
, pp. 62-66
-
-
Kim, J.G.1
Chae, Y.S.2
Sohn, S.K.3
Cho, Y.Y.4
Moon, J.H.5
Park, J.Y.6
Jeon, S.W.7
Lee, I.T.8
Choi, G.S.9
Jun, S.H.10
-
19
-
-
8444239305
-
VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer
-
15541813
-
Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E, Sivridis E (2004) VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 46:293-298
-
(2004)
Lung Cancer
, vol.46
, pp. 293-298
-
-
Koukourakis, M.I.1
Papazoglou, D.2
Giatromanolaki, A.3
Bougioukas, G.4
Maltezos, E.5
Sivridis, E.6
-
20
-
-
80055069795
-
Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: Associations with germline VHL polymorphisms and etiologic risk factors
-
22022277 1:CAS:528:DC%2BC3MXhsVWqsLfP 3192834
-
Moore LE, Nickerson ML, Brennan P, Toro JR, Jaeger E, Rinsky J, Han SS, Zaridze D, Matveev V, Janout V, Kollarova H, Bencko V, Navratilova M, Szeszenia-Dabrowska N, Mates D, Schmidt LS, Lenz P, Karami S, Linehan WM, Merino M, Chanock S, Boffetta P, Chow WH, Waldman FM, Rothman N (2011) Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors. PLoS Genet 7:e1002312
-
(2011)
PLoS Genet
, vol.7
, pp. 1002312
-
-
Moore, L.E.1
Nickerson, M.L.2
Brennan, P.3
Toro, J.R.4
Jaeger, E.5
Rinsky, J.6
Han, S.S.7
Zaridze, D.8
Matveev, V.9
Janout, V.10
Kollarova, H.11
Bencko, V.12
Navratilova, M.13
Szeszenia-Dabrowska, N.14
Mates, D.15
Schmidt, L.S.16
Lenz, P.17
Karami, S.18
Linehan, W.M.19
Merino, M.20
Chanock, S.21
Boffetta, P.22
Chow, W.H.23
Waldman, F.M.24
Rothman, N.25
more..
-
21
-
-
0001677717
-
Controlling the false discovery rate: A practical and powerful approach to multiple testing
-
Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodological) 57:289-300
-
(1995)
J R Stat Soc ser B (Methodological)
, vol.57
, pp. 289-300
-
-
Benjamini, Y.1
Hochberg, Y.2
-
22
-
-
83955162846
-
Sequencing of agents for metastatic renal cell carcinoma: Can we customize therapy?
-
22055147 1:CAS:528:DC%2BC3MXhs1emtLzI
-
Sonpavde G, Choueiri TK, Escudier B, Ficarra V, Hutson TE, Mulders PF, Patard JJ, Rini BI, Staehler M, Sternberg CN, Stief CG (2012) Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol 61:307-316
-
(2012)
Eur Urol
, vol.61
, pp. 307-316
-
-
Sonpavde, G.1
Choueiri, T.K.2
Escudier, B.3
Ficarra, V.4
Hutson, T.E.5
Mulders, P.F.6
Patard, J.J.7
Rini, B.I.8
Staehler, M.9
Sternberg, C.N.10
Stief, C.G.11
-
23
-
-
84869407359
-
Resistance and escape from antiangiogenesis therapy: Clinical implications and future strategies
-
23008289 1:CAS:528:DC%2BC38XhvValtbfK 3488272
-
Bottsford-Miller JN, Coleman RL, Sood AK (2012) Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol 30:4026-4034
-
(2012)
J Clin Oncol
, vol.30
, pp. 4026-4034
-
-
Bottsford-Miller, J.N.1
Coleman, R.L.2
Sood, A.K.3
-
24
-
-
84868712956
-
Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients
-
23154434 1:CAS:528:DC%2BC38XhvVyrs7rL
-
Porta C, Paglino C, Imarisio I, Ganini C, Sacchi L, Quaglini S, Giunta V, De Amici M (2013) Changes in circulating pro-angiogenic cytokines, other than VEGF, before progression to sunitinib therapy in advanced renal cell carcinoma patients. Oncology 84:115-122
-
(2013)
Oncology
, vol.84
, pp. 115-122
-
-
Porta, C.1
Paglino, C.2
Imarisio, I.3
Ganini, C.4
Sacchi, L.5
Quaglini, S.6
Giunta, V.7
De Amici, M.8
-
25
-
-
33645712628
-
Analysis of angiogenesis genes from paraffin embedded breast tumor and lymph nodes
-
16505966 1:CAS:528:DC%2BD28XjtlWnsb8%3D
-
Schneider BP, Skaar TC, Sledge GW, Badve S, Li L, Flockhart DA (2006) Analysis of angiogenesis genes from paraffin embedded breast tumor and lymph nodes. Breast Cancer Res Treat 96:209-215
-
(2006)
Breast Cancer Res Treat
, vol.96
, pp. 209-215
-
-
Schneider, B.P.1
Skaar, T.C.2
Sledge, G.W.3
Badve, S.4
Li, L.5
Flockhart, D.A.6
-
26
-
-
48649098245
-
Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma
-
18635227 1:CAS:528:DC%2BD1cXhtVKmsbvE
-
Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R (2008) Von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 180:860-866
-
(2008)
J Urol
, vol.180
, pp. 860-866
-
-
Choueiri, T.K.1
Vaziri, S.A.2
Jaeger, E.3
Elson, P.4
Wood, L.5
Bhalla, I.P.6
Small, E.J.7
Weinberg, V.8
Sein, N.9
Simko, J.10
Golshayan, A.R.11
Sercia, L.12
Zhou, M.13
Waldman, F.M.14
Rini, B.I.15
Bukowski, R.M.16
Ganapathi, R.17
-
27
-
-
47949099628
-
Modes of resistance to anti-angiogenic therapy
-
18650835 1:CAS:528:DC%2BD1cXovV2lsrk%3D 2874834
-
Bergers G, Hanahan D (2008) Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 8:592-603
-
(2008)
Nat Rev Cancer
, vol.8
, pp. 592-603
-
-
Bergers, G.1
Hanahan, D.2
|